Article
Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Annals of surgical oncology - 1 Jun 2016
Kasper Bernd, Gruenwald Viktor, Reichardt Peter, Bauer Sebastian, Hohenberger Peter, Haller Florian
Abstract excerpt
BACKGROUND: CTNNB1 gene mutations are the molecular key events in the majority of sporadic desmoid-type fibromatosis (DF). The specific S45F mutation has been reported to be associated with a more aggressive clinical course in DF. For the current study, the CTNNB1 mutation status was analyzed in DF samples from the prospective German Interdisciplinary Sarcoma Group (GISG) phase 2 study evaluating imatinib to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.